New drug combo tested for Tough-to-Treat advanced cancers
NCT ID NCT04902040
Summary
This early-phase study tested the safety and effectiveness of adding a new drug called plinabulin to a combination of radiation and immunotherapy. It was for patients with advanced cancers (like lung, bladder, and melanoma) that had continued to grow despite prior immunotherapy. The goal was to see if this three-part approach could better control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IIIB LUNG CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.